[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-345042-105":59,"doc-detail-345042-en":129},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":122,"head_meta":124,"extra_data":126,"updated_unix":128},105,"en","from-feasibility-to-translational-pathways-a-bibliometric-and-knowledge-mapping-analysis-of-urine-based-liquid-biopsy-in-urologic-cancers-2015-2025","From feasibility to translational pathways - a bibliometric and knowledge-mapping analysis of urine-based liquid biopsy in urologic cancers (2015-2025)","","Urine-based liquid biopsy enables non-invasive, repeat sampling in urologic cancers, yet clinical and scientific evidence remains fragmented across diseases, analytes, and platforms. This study maps the research landscape and frames thematic trajectories from 2015–2025 English-language literature. Using CiteSpace, VOSviewer, and bibliometrix, it analyzes collaboration patterns, co-citation networks, citation bursts, and keyword evolution, with robustness checks via sensitivity analyses and PubMed validation. The resulting evidence map highlights disease-specific directions and research gaps to guide future validation priorities.",{"@graph":69,"@context":121},[70,84,104],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/from-feasibility-to-translational-pathways-a-bibliometric-and-knowledge-mapping-analysis-of-urine-based-liquid-biopsy-in-urologic-cancers-2015-2025/345042/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":98,"encodingFormat":97,"isAccessibleForFree":99,"interactionStatistic":100},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/from-feasibility-to-translational-pathways-a-bibliometric-and-knowledge-mapping-analysis-of-urine-based-liquid-biopsy-in-urologic-cancers-2015-2025/345042.png","ImageObject",300,407,{"name":92,"@type":93},"Ivy","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-22",true,{"@type":101,"interactionType":102,"userInteractionCount":14},"InteractionCounter",{"@type":103},"ViewAction",{"@type":105,"mainEntity":106},"FAQPage",[107,113,117],{"name":108,"@type":109,"acceptedAnswer":110},"What problem does urine-based liquid biopsy aim to address in urologic cancers?","Question",{"text":111,"@type":112},"It provides non-invasive, repeatable sampling, addressing the limitations of imaging, serum biomarkers, and invasive histopathological biopsy in capturing dynamic tumor changes.","Answer",{"name":114,"@type":109,"acceptedAnswer":115},"How were the studies collected and analyzed in this bibliometric work?",{"text":116,"@type":112},"English-language articles and reviews from 2015–2025 were retrieved from WoSCC (SCIE), and CiteSpace, VOSviewer, and bibliometrix were used to map collaboration, co-citation, citation bursts, and keyword evolution.",{"name":118,"@type":109,"acceptedAnswer":119},"What major research directions emerged from the keyword evolution and analyses?",{"text":120,"@type":112},"The work identifies two clinical streams: prostate cancer diagnostics focused on urinary RNA/exosome panels and multivariable biopsy-decision models, and urothelial cancer monitoring using mutation/methylation assays and enhanced cytology for surveillance.","https://schema.org",{"og:url":83,"og:type":123,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":125,"canonical":83},"index,follow",{"doc_id":127,"site_id":62},345042,1790118675,{"code":4,"msg":5,"data":130},{"doc_id":127,"user_id":131,"nickname":92,"user_avatar":132,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":133,"file_id":134,"file_url":135,"file_type":136,"file_size":137,"view_count":14,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":138,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":26},549758252649,"https://ap-avatar.wpscdn.com/avatar/8000253669c5317157?_k=1778319167496531819","Liu et al. Journal of Translational Medicine (2026) 24:437  \n[https://doi.org/10.1186/s12967-026-08043-y](https://doi.org/10.1186/s12967-026-08043-y)  \nJournal of Translational Medicine  \nRESEARCH Open Access  \nFrom feasibility to translational pathways: a bibliometric and knowledge-mapping analysis of urine-based liquid biopsy in urologic cancers (2015–2025)  \nHanlin Liu1,2†, Yuqiang Fu1,2†, Jianwei Yang1,2†, Li Wang1,2, Junsheng Bao1,2, Liyun Ding3, Wei Shi1,2, Siyu Chen1,2,4* and Xiaoran Li 1,2,4*  \nAbstract  \nBackground Urine-based liquid biopsy enables non-invasive, repeat sampling in urologic cancers, yet evidence remains fragmented across diseases, analytes, and platforms. We mapped the research landscape and clinically framed thematic trajectories of the field.  \nMethods English-language articles and reviews (2015–2025) were retrieved from WoSCC (SCIE) using urologic cancer terms combined with urine/urinary and “liquid biopsy”. CiteSpace, VOSviewer and bibliometrix were used to map collaboration, co-citation, citation bursts and keyword evolution. Robustness was assessed via sensitivity analyses and matched PubMed validation.  \nResults Among 431 publications from 51 countries, output rose steadily and accelerated in 2021. Co-citation and citation-burst analyses suggested a shift from feasibility-oriented method expansion to standardization-oriented, platform-integrative synthesis. Collaboration showed a Europe–North America core with growing East Asian participation. Keywords converged on two clinical streams: prostate cancer diagnostics (urinary RNA/exosome panels and multivariable models for biopsy decision-making) and urothelial cancer monitoring (mutation/methylation assaysand enhanced cytology for surveillance and potential cystoscopy de-escalation) . Evidence for renal cell carcinoma and rarer urologic cancers remained sparse and largely exploratory, including methylation profiling, extracellular vesicles (EVs) and metabolomics.  \nConclusions This bibliometric evidence map delineates disease-specific trajectories and gaps to inform future validation priorities. Bibliometrics reflect research attention, not proven clinical utility.  \n†Hanlin Liu, Yuqiang Fu and Jianwei Yang contributed equally to this work and share first authorship.  \n*Correspondence: Siyu Chen [1432996042@qq.com](1432996042@qq.com)[ ](1432996042@qq.com)Xiaoran Li[lixiaoran05@163.com](lixiaoran05@163.com)  \nFull list of author information is available at the end of the article  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/licenses/by-nc-nd/4.0/](vecommons.org/licenses/by-nc-nd/4.0/.)[.](vecommons.org/licenses/by-nc-nd/4.0/.)  \nLiu et al. Journal of Translational Medicine (2026) 24:437 Page 2 of 24  \nKeywords Urine, Liquid biopsy, Urologic neoplasms, Bibliometric mapping, Knowledge evolution, Circulating tumor DNA, Extracellular vesicles, Biomarkers  \nIntroduction  \nUrologic cancers—including prostate cancer, bladder cancer, upper tract urothelial carcinoma (UTUC) and ren","cbCaisSz8r4Xb7zX","https://ap.wps.com/l/cbCaisSz8r4Xb7zX","pdf",6864950,24,"English","# Abstract\n# Introduction\n## Clinical need for non-invasive molecular biomarkers\n## Computational approaches in biomarker discovery\n# Methods\n## Literature retrieval strategy (2015–2025)\n## Bibliometric tools and analytical scope\n## Robustness and validation\n# Results\n## Publication trends and geographic collaboration\n## Methodological shift and keyword convergence\n# Conclusions","[{\"question\":\"What problem does urine-based liquid biopsy aim to address in urologic cancers?\",\"answer\":\"It provides non-invasive, repeatable sampling, addressing the limitations of imaging, serum biomarkers, and invasive histopathological biopsy in capturing dynamic tumor changes.\"},{\"question\":\"How were the studies collected and analyzed in this bibliometric work?\",\"answer\":\"English-language articles and reviews from 2015–2025 were retrieved from WoSCC (SCIE), and CiteSpace, VOSviewer, and bibliometrix were used to map collaboration, co-citation, citation bursts, and keyword evolution.\"},{\"question\":\"What major research directions emerged from the keyword evolution and analyses?\",\"answer\":\"The work identifies two clinical streams: prostate cancer diagnostics focused on urinary RNA/exosome panels and multivariable biopsy-decision models, and urothelial cancer monitoring using mutation/methylation assays and enhanced cytology for surveillance.\"}]","From feasibility to translational pathways - a bibliometric and knowledge-mapping analysis of urine-based liquid biopsy in urologic cancers (2015-2025) | PDF",1790056336]